{"schema_version":"secwatch.filing_event.v1","accession":"0001819790-25-000077","form_type":"8-K","ticker":"TARS","cik":"0001819790","company_name":"Tarsus Pharmaceuticals, Inc.","filed_at":"2025-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.879064+00:00","generated_at":"2026-05-23T00:57:08.309003+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Tarsus Q1 2025: XDEMVY sales $78.3M, up 217% YoY; net loss narrows to $25.1M","bullets":["Net product sales of XDEMVY $78.3M, up 217% vs Q1 2024 and 18% vs Q4 2024; ~72,000 bottles dispensed.","Net loss of $25.1M ($0.64 diluted loss per share), improved from $35.7M loss ($1.01 per share) in Q1 2024.","Cash, cash equivalents and marketable securities $407.9M as of March 31, 2025, bolstered by $134.8M equity offering.","SG&A expenses $85.0M, up from $51.6M, driven by DTC advertising and commercial expansion.","On track to initiate Phase 2 trial of TP-04 for Ocular Rosacea in H2 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001819790-25-000077","json":"https://secwatch.observer/filing/0001819790-25-000077.json","markdown":"https://secwatch.observer/filing/0001819790-25-000077.md","text":"https://secwatch.observer/filing/0001819790-25-000077.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000077/0001819790-25-000077-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1819790/000181979025000077/tars-20250501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T00:57:08.309003+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}